- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07588594
Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
Prospective Single-Arm Clinical Study of Thiotepa-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia
This is a prospective, single-arm clinical study. It aims to evaluate the effectiveness and safety of a conditioning regimen containing thiotepa (in combination with busulfan and fludarabine, with or without ATG) of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with chronic myelomonocytic leukemia (CMML) who have an intermediate-2 or high-risk prognosis.
The main goal is to evaluate 1 year RFS and OS. Other goals include assessing engraftment, overall survival, transplant-related complications, and side effects. A total of 31 participants will be enrolled.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Yuqian Sun, MD
- Numéro de téléphone: +86 88326666
- E-mail: sunyuqian83@hotmail.com
Sauvegarde des contacts de l'étude
- Nom: Xueyi Luo, MD
- Numéro de téléphone: +86 88326666
- E-mail: lll_xxx_yyy@126.com
Lieux d'étude
-
-
-
Beijing, Chine, 100044
- Recrutement
- Peking University People's Hospital
-
Contact:
- Yuqian Sun, MD
- Numéro de téléphone: +86 010-88326666
- E-mail: sunyuqian83@hotmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age ≥ 18 years, any sex/gender.
- Confirmed diagnosis of chronic myelomonocytic leukemia (CMML) according to the 2022 WHO classification.
- Intermediate-2 or high-risk CMML based on CPSS or CPSS-mol score, and planned to receive allo-HSCT.
- Has a suitable hematopoietic stem cell donor:
- For haploidentical donor: at least 5/10 HLA match at HLA-A, -B, -C, -DQB1, and -DRB1.
- For unrelated donor: at least 9/10 HLA match at the same five loci.
- For matched sibling donor: 10/10 HLA match at the same five loci.
- Hematopoietic cell transplantation comorbidity index (HCT-CI) ≤ 2, with generally good health and no significant organ abnormalities or major comorbidities.
- Adequate organ function as defined below:
- Left ventricular ejection fraction (LVEF) ≥ 50%, and no uncontrolled tachycardia or bradycardia-tachycardia syndrome.
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT ≤ 2 × ULN; AST ≤ 2 × ULN.
- Serum creatinine ≤ 1.5 × ULN.
- Baseline oxygen saturation > 92%.
- Pulmonary function: DLCO (corrected for hemoglobin) ≥ 40%, FEV1 ≥ 50%.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Agrees not to participate in any other interventional study during the treatment period.
- Willing and able to provide written informed consent, understand the nature, purpose, and procedures of the study, and voluntarily comply with study requirements.
Exclusion Criteria:
- Previous allogeneic HSCT for CMML that later relapsed.
- Unwilling or unable to receive the study treatment regimen.
- Active hepatitis B or C, or chronic active hepatitis; known human immunodeficiency virus (HIV) infection.
- Active uncontrolled infection, including: hemodynamic instability related to infection, new or worsening signs/symptoms of infection, new infection lesions on imaging, or persistent fever without explanation despite no symptoms/signs.
- History of stroke or intracranial hemorrhage within 6 months before enrollment.
- Known pregnancy (positive urine pregnancy test), or currently breastfeeding.
- Diagnosis of another malignancy within the past 2 years, except for localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, breast cancer, or localized prostate cancer (Gleason score ≤ 6) that has been treated with curative intent.
- Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Single Arm: Thiotepa + Busulfan + Fludarabine ± ATG
Patients with intermediate-2 or high-risk chronic myelomonocytic leukemia (CMML) per CPSS/CPSS-mol criteria, who are scheduled to receive allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a thiotepa-containing conditioning regimen.
|
Intravenous thiotepa 5 mg/kg/d on days -11,-10; busulfan 3.2 mg/kg/d on days -8,-7,-6; fludarabine 30 mg/m²/d on days -6 to -2; ATG per donor type (haplo/unrelated: 2.5 mg/kg/d days -5 to -2; MSD: 1.125 mg/kg/d days -5 to -2).
Allogeneic stem cells infused on day 0. GVHD prophylaxis: CsA, MMF, MTX per protocol.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
One-year relapse-free survival (RFS) after allogeneic hematopoietic stem cell transplantation
Délai: At 12 months after allogeneic hematopoietic stem cell transplantation.
|
Time from stem cell infusion to hematologic/extramedullary relapse or death, censored at 12 months for event-free participants.
|
At 12 months after allogeneic hematopoietic stem cell transplantation.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
One-year overall survival (OS)
Délai: At 12 months after allogeneic hematopoietic stem cell transplantation.
|
Overall survival is defined as the time from stem cell infusion to death from any cause.
Participants alive at 12 months are censored at the last follow-up.
|
At 12 months after allogeneic hematopoietic stem cell transplantation.
|
|
One-year cumulative incidence of relapse (RR)
Délai: At 12 months after allogeneic hematopoietic stem cell transplantation.
|
Relapse is defined as recurrence of CMML .
Non-relapse mortality is treated as a competing risk.
|
At 12 months after allogeneic hematopoietic stem cell transplantation.
|
|
One-year non-relapse mortality (NRM)
Délai: At 12 months after allogeneic hematopoietic stem cell transplantation.
|
Non-relapse mortality is defined as death from any cause other than disease relapse or progression.
Relapse is treated as a competing risk.
|
At 12 months after allogeneic hematopoietic stem cell transplantation.
|
|
Regimen toxicity at day +30
Délai: Up to day +30 post-transplant
|
Toxicity is graded according to NCI CTCAE v5.0.
Any grade 3-5 non-hematologic toxicity occurring within 30 days after stem cell infusion is reported.
|
Up to day +30 post-transplant
|
|
Incidence and severity of adverse events (AEs)
Délai: At 12 months after allogeneic hematopoietic stem cell transplantation.
|
AEs are coded using MedDRA and graded per NCI CTCAE v5.0.
All AEs, serious AEs (SAEs), and AEs leading to treatment discontinuation are summarized.
|
At 12 months after allogeneic hematopoietic stem cell transplantation.
|
|
Incidence and severity of acute graft-versus-host disease (aGVHD)
Délai: Up to day +100 post-transplant
|
Acute GVHD is diagnosed and graded according to the modified Glucksberg criteria or MAGIC criteria.
Both overall incidence and grade II-IV/III-IV severity are reported.
|
Up to day +100 post-transplant
|
|
Incidence and severity of chronic graft-versus-host disease (cGVHD)
Délai: From day +100 up to 1 year post-transplant
|
Chronic GVHD is diagnosed and graded according to the NIH consensus criteria (mild, moderate, severe).
Overall incidence and severity distribution are reported.
|
From day +100 up to 1 year post-transplant
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Yuqian Sun, MD, Peking University People's Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs
- Maladie chronique
- Attributs de la maladie
- Tumeurs par type histologique
- Maladies hématologiques
- Leucémie myéloïde
- Maladies myélodysplasiques-myéloprolifératives
- Maladies de la moelle osseuse
- Leucémie
- Conditions pathologiques, signes et symptômes
- Maladies hémiques et lymphatiques
- Leucémie myélomonocytaire chronique
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Hydrocarbures, acyclique
- Hydrocarbures
- Alcanes
- Alcools
- Butylène glycols
- Glycols
- Mésylates
- Alcanesulfonates
- Acides alcanesulfoniques
- Acides sulfoniques
- Acides de soufre
- Phosphoramides
- Composés organophosphores
- Triéthylènephosphoramide
- Aziridines
- Azirines
- Busulfan
- Thiotépa
- fludarabine
Autres numéros d'identification d'étude
- 2025PHD048-001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .